

May 16, 2026

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
---	---

Dear Sir / Madam,

**Sub: CuraTeQ Biologics Receives CDSCO Marketing Authorisation (Form CT 23) for Bevqolva® (Bevacizumab Biosimilar)**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva®, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ's facility in Hyderabad and marketing of Bevqolva® in 100 mg/4mL and 400 mg/16 mL vial presentations.

Please take the above information on record.

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**  
**Company Secretary**

(CIN : L24239TG1986PLC015190)

**AUROBINDO PHARMA LIMITED**  
[www.aurobindo.com](http://www.aurobindo.com)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)